As of June 15, 2025, Brooklyn Immunotherapeutics Inc has a Discounted Cash Flow (DCF) derived fair value of $287.45 per share. With the current market price at $7.09, this represents a potential upside of 3954.3%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $252.96 |
| DCF Fair Value (10-year) | $287.45 |
| Potential Upside (5-year) | 3467.9% |
| Potential Upside (10-year) | 3954.3% |
| Discount Rate (WACC) | 6.0% - 7.4% |
Revenue is projected to grow from $5 million in 12-2024 to $8 million by 12-2034, representing a compound annual growth rate of approximately 4.8%.
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 12-2024 | 5 | - |
| 12-2025 | 6 | 5% |
| 12-2026 | 6 | 2% |
| 12-2027 | 6 | 2% |
| 12-2028 | 6 | 2% |
| 12-2029 | 6 | 3% |
| 12-2030 | 7 | 4% |
| 12-2031 | 7 | 6% |
| 12-2032 | 7 | 2% |
| 12-2033 | 7 | 4% |
| 12-2034 | 8 | 6% |
Net profit margin is expected to improve from 656% in 12-2024 to 479% by 12-2034, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 12-2024 | 36 | 656% |
| 12-2025 | 28 | 479% |
| 12-2026 | 28 | 479% |
| 12-2027 | 29 | 479% |
| 12-2028 | 30 | 479% |
| 12-2029 | 30 | 479% |
| 12-2030 | 32 | 479% |
| 12-2031 | 34 | 479% |
| 12-2032 | 34 | 479% |
| 12-2033 | 36 | 479% |
| 12-2034 | 38 | 479% |
. Projected CapEx is expected to maintain at approximately 0% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 12-2025 | 0 |
| 12-2026 | 0 |
| 12-2027 | 0 |
| 12-2028 | 0 |
| 12-2029 | 0 |
| 12-2030 | 0 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 0 |
| Days Inventory | 0 |
| Days Payables | 159 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 2025 | 38 | 10 | 0 | 6 | 22 |
| 2026 | 39 | 10 | 0 | (3) | 31 |
| 2027 | 40 | 11 | 0 | (2) | 31 |
| 2028 | 40 | 11 | 0 | 2 | 27 |
| 2029 | 42 | 11 | 0 | (1) | 31 |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 252.96 | 3467.9% |
| 10-Year DCF (Growth) | 287.45 | 3954.3% |
| 5-Year DCF (EBITDA) | 276.88 | 3805.2% |
| 10-Year DCF (EBITDA) | 308.16 | 4246.4% |
Is Brooklyn Immunotherapeutics Inc (BTX) a buy or a sell? Brooklyn Immunotherapeutics Inc is definitely a buy. Based on our DCF analysis, Brooklyn Immunotherapeutics Inc (BTX) appears to be significantly undervalued with upside potential of 3954.3%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider a strong buy at the current market price of $7.09.